A roundup of biopharma news and updates includes Merck and Eisai’s Keytruda-Lenvima combo hitting the mark in a Phase III study for advanced endometrial cancer.
ViiV Healthcare announced that an independent data safety monitoring board (DSMB) recommended the early unblinding of data from the HIV Prevention Trials Network 084 trial of the investigational, long-acting injectable cabotegravir for HIV prevention in women.
ViiV Healthcare announces investigational injectable cabotegravir is superior to oral standard of care for HIV prevention in women Interim analysis from HPTN 084 study shows long-acting injectable cabotegravir administered every two months is 89% more effective than daily pills in preventing HIV acquisition in women Findings follow data from HPTN 083, a partner HIV prevention […]
Oxford University will study whether the world’s best-selling prescription medicine adalimumab was an effective treatment for Covid-19 patients in the latest effort to repurpose existing drugs as potential coronavirus therapies.
Johnson & Johnson is in talks with the government of Japan and the Bill and Melinda Gates Foundation about locking up allocations of a potential COVID-19 vaccine in advance of the company producing any of the medicines, the company’s Chief Financial Officer Joseph Wolk told Reuters in an interview.
A summit hosted by British Prime Minister Boris Johnson is expected to set a goal of at least $7.4 billion to go to Gavi, the Vaccine Alliance.
Numerous major global biopharma companies reported first-quarter 2020 earnings. Typically, the COVID-19 pandemic has affected the companies, although not necessarily in a straightforward way. Many of the companies reported increased sales for the quarter as customers increased stockpiles and inventory in preparation for the pandemic, while other forms of sales and clinical trials were negatively impacted. Here’s a look.
The U.S. National Institutes of Health (NIH) and the Bill & Melinda Gates Foundation announced plans to invest $200 million over four years in support of affordable gene therapies for sickle cell disease and HIV.
Vir Biotechnology priced the company’s initial public offering (IPO) at $20 a share, at the bottom end of expectations, the latest underwhelming investment performance for a stock held by SoftBank Group Corp.’s Vision Fund.
The Bill & Melinda Gates Foundation granted Watertown, Massachusetts-based Lyndra Therapeutics a $13 million grant to develop a once-a-month oral contraceptive.